Prøve GULL - Gratis
Not too worried about markets as flows unlikely to taper off soon
Mint Ahmedabad
|July 28, 2025
The real concern is on the external front. We are witnessing rising trade barriers, like recent tariffs Ramesh Mantri CIO, WhiteOak Capital Asset Management Co.
India faces external risks even as the domestic economy stays on a solid footing, according to Ramesh Mantri of WhiteOak Capital Asset Management Co.
Improving domestic growth, rising liquidity, and potential rate cuts are expected to aid recovery, but the "real concern is on the external front" from growing global protectionism to US-China tensions, said Mantri, chief investment officer (CIO) at the company.
Mantri isn't worried about domestic markets. Even though small-cap valuations are a concern, he expects stable domestic flows—from mutual funds, insurance (including unit-linked plans), and Employee Provident Fund Organisation—to support Indian equities as these are unlikely to taper off anytime soon, he said.
Edited excerpts:
What do you see as the biggest risks for the market right now?
The domestic economy is in good shape—growth is improving, liquidity has picked up, and rate cuts should support recovery, though with a lag. The real concern is on the external front. We are witnessing rising trade barriers, like recent tariffs even on Japan—a key US ally—which shows how broad-based protectionism is becoming. Then there is the uncertainty around US-China relations; even if a deal is signed, we don't know how long it will last.
Geopolitical risks are unpredictable and could disrupt exports. Although these risks have been manageable so far, this may change. India has a chance to boost its manufacturing and R&D, but despite some progress and new government schemes, it still trails behind countries like China in electric vehicles (EVs) and industrial technology.
On the markets, the main concern is valuations in small caps. However, Indian markets are supported by strong, stable domestic flows—from mutual funds, insurance (Ulips), and EPFO—which aren't going away anytime soon. So overall, I am not too worried.
What is your take on current valuations—do they seem stretched?
Denne historien er fra July 28, 2025-utgaven av Mint Ahmedabad.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Mint Ahmedabad
Mint Ahmedabad
'If you're on trend, you are in trouble'
Patou creative head Guillaume Henry discusses the essence of couture and why simple is best
4 mins
December 13, 2025
Mint Ahmedabad
GST cuts, easing inflation drive rural demand revival
India’s rural economy expanded and recovered strongly in late 2025, with consumption, incomes and investment improving after a key tax reform and as inflation eased, a survey showed.
2 mins
December 13, 2025
Mint Ahmedabad
Chair man, of the bored
STREAM OF STORIES
3 mins
December 13, 2025
Mint Ahmedabad
Anju Dodiya creates disquieting worlds
Artist Anju Dodiya discusses the ideas, influences and inspiration behind her new solo show, 'The Geometry of Ash'
5 mins
December 13, 2025
Mint Ahmedabad
Bar hopping with Lounge
\"The things that make a cocktail really great are often very simple details—the frozen glass, the lemon twist—that transform two fingers of alcohol into an ice-glazed elixir,\" writes Alice Lascelles in her excellent guide to making cocktails at home, The Cocktail Edit.
1 mins
December 13, 2025
Mint Ahmedabad
New Delhi and France revise 1992 tax treaty
India and France have struck a deal to revise their 1992 treaty which will halve the tax on dividends paid by Indian units to French parents, potentially saving millions for companies with major operations in the South Asian nation, documents show.
1 min
December 13, 2025
Mint Ahmedabad
Ozempic debuts with a ₹2,200-a-week price tag
for chronic weight management, Novo Nordisk is positioning Ozempic as a treatment of type 2 diabetes with weight loss benefits, competing with Eli Lily’s Mounjaro that was launched in India in March.
1 mins
December 13, 2025
Mint Ahmedabad
How 'puri-aloo' and 'chaat' unite Lucknow
Whenever my friends want to eat puri-aloo, they invite themselves over to my home.
5 mins
December 13, 2025
Mint Ahmedabad
Novo Nordisk debuts Ozempic at ₹2,200 a week
Danish drugmaker Novo Nordisk on Friday launched its blockbuster diabetes drug Ozempic in India, with a starting price of ₹2,200 per week.
1 mins
December 13, 2025
Mint Ahmedabad
Govt’s insurance reform allows 100% FDI, composite licences
The government has paved the way for 100% foreign direct investment in the insurance sector, composite licences and easier capital requirements, among others sweeping reforms, as the Union cabinet cleared the enabling legislation, said two officials aware of the matter.
1 mins
December 13, 2025
Listen
Translate
Change font size
